title: [Monotherapy using amoxicillin/clavulanic acid as treatment of first choice in community-acquired lung abscess. Apropos of 57 cases].
abstract: In a multicentre open prospective trial the effectiveness of AM-CA as first-line treatment of community-acquired lung abscess was evaluated in immunocompetent adult patients. AM-CA was administered intravenously in doses of 4 g/day for at least 7 days, then orally in doses of 2 g/day for at least 14 days. Radio-clinical and laboratory evaluations were made during treatment, and 30 and 60 days after it was discontinued. The results of this trial concerned 57 patients (48 men, 9 women; mean age 52 years). The facilitating factors were those usually found in lung abscess. Twenty-seven patients had previously received an antibiotic treatment which had failed. The clinical picture, built up gradually in 42/37 patients, consisted of infectious syndrome (52 cases), altered general condition (39 cases), purulent expectoration (47 cases), sometimes foetid (10 cases), and thoracic clinical abnormalities (57 cases. X-ray films of the chest showed round abscess images (44 cases) or looked like necrotizing pneumonia (13 cases) with pleural reaction (8 cases). Protecting bacteriological sampling by BFW brushing and transtracheal or transparietal sample collecting was performed in 41 of the 57 patients. The pathogens, isolated in 31 cases, were: S. pneumoniae 5; Streptococcus spp. 12; Staph. aureus 4; H. influenzae 7; Enterobacteriaceae 6; anaerobes 7. These organisms were associated in 8 cases. With the exception of Enterobacter cloacae, all were sensitive to AM-CA in-vitro. The outcome was satisfactory in 52 patients.
authors.affiliation: Services de Pneumologie: Hôpitaux de Nantes, Aix-en-Provence, Lyon.
authors.forename: P
authors.initials: P
authors.lastname: Germaud
authors.forename: J
authors.initials: J
authors.lastname: Poirier
authors.forename: P
authors.initials: P
authors.lastname: Jacqueme
authors.forename: J C
authors.initials: JC
authors.lastname: Guerin
authors.forename: Y
authors.initials: Y
authors.lastname: Benard
authors.forename: C
authors.initials: C
authors.lastname: Boutin
authors.forename: C
authors.initials: C
authors.lastname: Brambilla
authors.forename: R
authors.initials: R
authors.lastname: Escamilla
authors.forename: P
authors.initials: P
authors.lastname: Zuck
mesh_terms: D000293:Adolescent; D000328:Adult; D000658:Amoxicillin / Q000627:therapeutic use*; D002969:Clavulanic Acids / Q000627:therapeutic use*; D017714:Community-Acquired Infections / Q000188:drug therapy*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008169:Lung Abscess / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies
chemical_list: D002969:Clavulanic Acids; D000658:Amoxicillin
vernacular_title: Monothérapie par amoxicilline/acide clavulanique (AM-AC) en traitement de première intention dans les abcès pulmonaires communautaires. A propos de 57 cas.